0001425205 false 0001425205 2021-05-18 2021-05-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K
Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): May 18, 2021

 

IOVANCE BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State of Incorporation)
 
001-36860   75-3254381
Commission File Number   (I.R.S. Employer Identification No.)
     
999 Skyway Road, Suite 150    
San Carlos, California   94070
(Address of Principal Executive Offices)   (Zip Code)
     
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Market, LLC

 

 

 

 

 

 

Item 8.01. Other Events.  

 

On May 18, 2021, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release providing a regulatory update for its lifileucel potency assays. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

On May 19, 2021, the Company issued a press release announcing clinical data updates for lifileucel in advanced melanoma at the upcoming American Society of Clinical Oncology 2021 Annual Meeting. The full text of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.  

 

  (d) Exhibits.  

 

Exhibit
No.
  Description
99.1   Press Release of Iovance Biotherapeutics, Inc., dated May 18, 2021.
99.2   Press Release of Iovance Biotherapeutics, Inc., dated May 19, 2021.
104   Cover Page Interactive Data File - the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 20, 2021 IOVANCE BIOTHERAPEUTICS, INC.  
     
     
  By: /s/ Frederick G. Vogt
    Frederick G. Vogt, General Counsel

 

 

 

Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Iovance Biotherapeutics Charts.
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Iovance Biotherapeutics Charts.